Information Provided By: 
Fly News Breaks for January 26, 2018
LJPC
Jan 26, 2018 | 07:43 EDT
JPMorgan analyst Anupam Rama adds Underweight-rated La Jolla Pharmaceutical to his firm's Analyst Focus List as a Sell idea. The analyst, which raised his price target for the shares to $25 from $20, continues to see "significant risk" to the Giapreza launch and maintain there are multiple potential downside scenarios that could playout. He notes the shares are up 31% since approval. The analyst sees "clear indications of price sensitivity" in the market for vasodilatory/septic shock.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
